Vectorite Biomedical

Vectorite Biomedical Stock-Based Compensation

The Stock-Based Compensation (SBC) of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is 540,000.00 TWD. In the previous year, Stock-Based Compensation (SBC) was 12.41 M TWD — a change of -95.65% (lower).

Stock-Based Compensation

540,000.00TWD

YoY

-95.65%

Last updated:

Stock-Based Compensation (SBC) of Vectorite Biomedical is 2020 540,000.00 TWD. Stock-Based Compensation (SBC) of Vectorite Biomedical was 2019 12.41 M TWD. It decreases by -95.65% lower compared to the previous year.

The Vectorite Biomedical Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2014
12.41 M TWD
Jan 1, 2020
540,000.00 TWD
The Vectorite Biomedical Stock-Based Compensation history
YEARStock-Based CompensationYoY
540,000.00TWD-95.65%
12.41 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

Stock-Based Compensation (SBC) of Vectorite Biomedical is 540,000.00 TWD in 2020.

Stock-Based Compensation (SBC) of Vectorite Biomedical changed from 12.41 M TWD to 540,000.00 TWD, representing a -95.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Vectorite Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Vectorite Biomedical

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Vectorite Biomedical